Trial Profile

A Retrospective Study Investigating the Combination of Irinotecan, Vincristine and Anlotinib for Epithelioid Sarcoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Irinotecan (Primary) ; Vincristine (Primary)
Indications Sarcoma
Focus Therapeutic Use

Most Recent Events

20 Feb 2023 Last checked against ClinicalTrials.gov: US record.
14 Feb 2023 Status changed from completed to withdrawn prior to enrolment.
20 Dec 2022 planned number of patients are 10 and there is no any development line for Epithelioid Sarcoma in RDI profile hence I have assumed phase as ll. Line of therapy is not clear as of now. Please update further.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com